08.07.2025

Sanofi: Positive Study Data Strengthen Buy Recommendation

UBS Confirms Buy Recommendation for Sanofi

The Swiss bank UBS has rated Sanofi as “Buy” and set a price target of 115 Euros. This assessment is based on promising study data that is particularly significant for investors.

Focus on Study Data

Matthew Weston, an analyst at UBS, emphasizes the importance of the new study data from a competing drug to Sanofi’s Ayvakit, which is currently the only approved medication for the treatment of mastocytosis. The data shows comparable efficacy of the new drug Bezuclastinib, developed by Blueprint Medicines, a company acquired in June.

Price Target and Justification

  • Classification: Buy
  • Price Target: 115 Euros
  • Reason: Positive study data for the treatment of mastocytosis
  • Importance: Comparable efficacy of Bezuclastinib versus Ayvakit
  • Source of Data: Blueprint Medicines

These developments in drug research strengthen confidence in Sanofi’s market position and justify the buy recommendation according to UBS.